ESTRO 2024 - Abstract Book

S2557

Clinical - Urology

ESTRO 2024

Conclusion:

There is a lack of level one evidence on managing SD in advanced PCa, with almost no trials to guide the use of the most common interventions, including PDE5i, penile injections and vacuum erectile devices. The strongest evidence showed intermittent ADT improved erectile function, libido and sexual activity, when compared with men using continuous ADT. However a range of treatment schedules in the trials means the optimal management remains uncertain. There was weak evidence to support the use of psycho-educational interventions to improve sexual activity and relationship satisfaction but there was no benefit in terms of sexual function. There was also weak evidence to suggest exercise interventions may improve sexual function in the short-term. More level one evidence is needed to guide the management of sexual dysfunction in the advanced disease setting.

Keywords: Sexual dysfunction, quality of life, prostate

References:

1. Sharma, P., et al., Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. Journal of urology, 2009. 182(5): p. 2265 ‐ 2272.

2. Calais da Silva, F.E., et al., Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. European urology, 2009. 55(6): p. 1269 ‐ 1277. 3. Calais da Silva, F., et al., Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. European urology, 2014. 66(2): p. 232 ‐ 239.

4. Crook, J.M., et al., Intermittent androgen suppression for rising PSA level after radiotherapy. New England journal of medicine, 2012. 367(10): p. 895 ‐ 903.